Principia Biopharma

An arrow incrementally going up stairs before pointing straight up Blue background

Sanofi nails phase 3 LUNA landing, sparking race to regulators

Sanofi plans to file for approval of a “multi-indication blockbuster” that it predicts could contribute to more than 10 billion euros of launch sales.

Nick Paul Taylor Apr 23, 2024 2:23am

Sanofi reports setbacks to Denali, Kymab and Principia assets

Oct 27, 2023 6:25am

Still under partial hold, Sanofi makes case for safety of MS med

Apr 28, 2023 11:16am

Sanofi, after $8B outlay, sees M&A strategy deliver 2 more duds

Apr 27, 2023 7:41am

Sanofi pulls phase 3 trial of $3.7B drug as competition heats up

Feb 3, 2023 6:50am

FDA pumps brakes on Sanofi's $3.7B multiple sclerosis bet

Jun 30, 2022 7:46am